Document Detail

Peptides as targets for antihypertensive drug development.
MedLine Citation:
PMID:  1291647     Owner:  NLM     Status:  MEDLINE    
AIM: To assess the potential for development of new classes of pharmacological drugs in the treatment of hypertension and cardiovascular disease. BACKGROUND: Basis of pharmacological blood pressure reduction: Since the discovery of the renin-angiotensin system by Tigerstedt almost 100 years ago, a large number of vasoactive peptides have been discovered. By interaction with such peptides of endocrine, perivascular or endothelial origin, blood pressure may be modulated. BLOCKADE OF THE RENIN-ANGIOTENSIN SYSTEM: The success of the angiotensin converting enzyme (ACE) inhibitors in hypertension and congestive heart failure is generally attributed to reduced generation of angiotensin II. The recent development of specific and highly potent Ang II type 1 subtype receptor antagonists such as losartan (DuP753, MK954) have provided a new opportunity to inhibit the renin-angiotensin system, and this is currently being explored in hypertensive patients. In addition, blockade of the first and rate-limiting reaction of the renin-angiotensin system, inhibition of renin activity, is also a target for the development of antihypertensive drugs. However, this development is hampered at present by a compensatory increase in active renin that clinically offsets the antihypertensive action of renin inhibitors. PHARMACOLOGICALLY INDUCED INCREASE IN ATRIAL NATRIURETIC PEPTIDE (ANP): The availability of circulating or tissue ANP may be increased by inhibiting its metabolic clearance by NEP-24.11 inhibitor drugs. These agents induce a reduction in blood pressure and diuretic effects in animal models, and may become a new class of drugs for the clinical management of patients with hypertension and congestive heart failure. OTHER POTENTIAL PHARMACOLOGICAL TARGETS IN THE MANAGEMENT OF HYPERTENSION: There are several potential pharmacological targets that may lead to the development of novel antihypertensive agents in the future. These include the interaction or blockade of vasopressor peptides. Routes of development include neuropeptide Y1 receptor antagonists, which block the postjunctional vasopressor effect of neuropeptide Y, or endothelin antagonists, which block endothelin pressor actions at the endothelin A receptor site. The cardiovascular actions of the functional neuropeptide Y inhibitor alpha-trinositol (PP 56) provide a potential new mechanism for reducing blood pressure in hypertension. In addition, the recent discovery of small molecular agents with high potency and specificity for the endothelin A receptor subtype may also be of value in specific vascular disease states. CONCLUSIONS: Future development is likely to provide us with novel drugs based on interactions with vasoactive peptides that may improve the management of specific cardiovascular disease states.
T Hedner; X Sun; I L Junggren; A Pettersson; L Edvinsson
Related Documents :
893737 - Synergistic effects of hydralazine and alpha- or beta-adrenergic blockers: the role of ...
519867 - Modification of the normal postural changes in plasma renin activity by the application...
3718027 - Pathogenesis of nonocclusive ischemic colitis.
1022407 - The renin-angiotensin systems in adrenal-regeneration hypertension.
23035867 - The effect of changes in intraocular pressure on the risk of primary open-angle glaucom...
15752957 - Systematic review of the effect of daily alcohol intake on blood pressure.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Journal of hypertension. Supplement : official journal of the International Society of Hypertension     Volume:  10     ISSN:  0952-1178     ISO Abbreviation:  J Hypertens Suppl     Publication Date:  1992 Dec 
Date Detail:
Created Date:  1993-03-30     Completed Date:  1993-03-30     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8501422     Medline TA:  J Hypertens Suppl     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  S121-32     Citation Subset:  IM    
Department of Pharmacology, University of Göteborg, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Amino Acid Sequence
Angiotensin II / antagonists & inhibitors
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
Antihypertensive Agents* / chemistry,  therapeutic use
Endothelins / antagonists & inhibitors
Hypertension / drug therapy*
Molecular Sequence Data
Neprilysin / antagonists & inhibitors
Neuropeptide Y / antagonists & inhibitors
Receptors, Angiotensin / antagonists & inhibitors
Renin / antagonists & inhibitors
Renin-Angiotensin System / drug effects
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 0/Antihypertensive Agents; 0/Endothelins; 0/Neuropeptide Y; 0/Receptors, Angiotensin; 11128-99-7/Angiotensin II; EC; EC

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The kidney as a sensor: functional evidence.
Next Document:  Adrenergic receptors and their signal transduction mechanisms in hypertension.